Cynaroside (Synonyms: Luteolin 7-glucoside; Luteolin 7-O-β-D-glucoside)

Name: Cynaroside
Brand: MedChemExpress
SKU: HY-N0540
Rating: 5.0 (14 reviews)

製品番号: HY-N0540 純度: 99.37%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Cynaroside (Luteolin 7-glucoside) is a flavonoid compound that exhibits anti-oxidative capabilities. Cynaroside is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC₅₀ of 32 nM. Cynaroside also is a promising inhibitor for H₂O₂-induced apoptosis, has cytoprotection against oxidative stress-induced cardiovascular diseases. Cynaroside also has antibacterial, antifungal and anticancer activities, antioxidant and anti-inflammatory activities.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 5373-11-5

容量	価格（税別）	在庫状況	数量

>無料サンプル (0.1 - 0.2 mg)		今すぐ申し込む
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 99	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 99	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$90	在庫あり	Estimated Time of Arrival: December 31
10 mg	$140	在庫あり	Estimated Time of Arrival: December 31
25 mg	$280	在庫あり	Estimated Time of Arrival: December 31
50 mg	$450	在庫あり	Estimated Time of Arrival: December 31
100 mg	$670	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 14 publication(s) in Google Scholar

Other Forms of Cynaroside:

Cynaroside (Standard) 在庫あり

顧客検証

Cell Proliferation/Viability Assay

Cell Imaging/Staining

RT-PCR

: Cynaroside purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 24:178196. [Abstract]; RAW 264.7 cells were treated with Cynaroside at the indicated concentrations. After 24 h of incubation, cell viability was assessed using the MTT assay.

: Cynaroside purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 24:178196. [Abstract]; RAW 264.7 cells were treated with Cynaroside (10 or 100 μM) for 30 min before they were treated with GrB (25 nM) and perforin (1 nM) for 24 h. Cleaved caspase-3 protein was detected by Western blotting.

: Cynaroside purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 24:178196. [Abstract]; Human plasma fibronectin was incubated with GrB and either Cynaroside (10 or 100 μM) or IEPD (100 μM) in vitro, and the results were visualized by Western blotting.

: Cynaroside purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 24:178196. [Abstract]; MCF-7 cells were plated on fibronectin-coated Transwell plates in serum-free DMEM and allowed to migrate toward 5 % FBS for 24 h in the presence of the indicated concentrations of Cynaroside (10 or 100 μM) and GrB (25 nM). The cells on the underside of the membrane were stained with 0.5 % crystal violet.

: Cynaroside purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2025 Sep 24:178196. [Abstract]; Cynaroside (10 mg/kg). The expression levels of TSLP and IL-6 mRNA in ear skin tissue on day 26 were detected by qRT-PCR.

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

Parasite アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target

RNA Polymerase

Cellular Effect

Cell Line	Type	Value	Description	References
B16-4A5	IC₅₀	> 100 μM Compound: 6	Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis	[PMID: 25987378]
CCRF-CEM	IC₅₀	> 10 μg/mL Compound: 10	Cytotoxicity against human CEM cells after 3 days by MTT assay Cytotoxicity against human CEM cells after 3 days by MTT assay	[PMID: 11421746]
H9	EC₅₀	7 μM Compound: 6	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
H9	IC₅₀	25 μM Compound: 6	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
H9c2	EC₅₀	5.04 μM Compound: 7	Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 20932762]
HL-60	IC₅₀	> 10 μg/mL Compound: 10	Cytotoxicity against human HL60 cells after 3 days by MTT assay Cytotoxicity against human HL60 cells after 3 days by MTT assay	[PMID: 11421746]
HeLa S3	IC₅₀	> 10 μM Compound: 13	Cytotoxicity against human HeLa S3 cells assessed as cell viability incubated for 48 hrs by microscopic analysis Cytotoxicity against human HeLa S3 cells assessed as cell viability incubated for 48 hrs by microscopic analysis	[PMID: 35704432]
HepG2	IC₅₀	20.8 μM Compound: 6	Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24974349]
Huh-7	CC₅₀	> 50 μM Compound: 9	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
MDCK	CC₅₀	> 1116 μM Compound: 5	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 18640042]
MDCK	CC₅₀	> 446 μM Compound: Luteolin-7-glucoside	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 25096296]
RAW264.7	CC₅₀	> 100 μM Compound: 20	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33667099]
RAW264.7	IC₅₀	6.1 μM Compound: 9	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 31747281]
RAW264.7	IC₅₀	8.3 μM Compound: 13	Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method	[PMID: 25176187]
RAW264.7	IC₅₀	87.5 μM Compound: 20	Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay	[PMID: 33667099]
RAW264.7	IC₅₀	> 20 μM Compound: luteolin-7-O-beta-D-glucopyranoside	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method	[PMID: 19778086]
RD	EC₅₀	0.43 mM Compound: Luteoloside	Antiviral activity against EV71 infected in human RD cells assessed as protection against virus-induced cytopathic effect after 48 hrs by MTS assay Antiviral activity against EV71 infected in human RD cells assessed as protection against virus-induced cytopathic effect after 48 hrs by MTS assay	[PMID: 27776325]
SW1573	IC₅₀	> 10 μg/mL Compound: 10	Cytotoxicity against human SW1573 cells after 3 days by MTT assay Cytotoxicity against human SW1573 cells after 3 days by MTT assay	[PMID: 11421746]

体外実験

Cynaroside promots macrophage phenotypic transition from pro-inflammatory M1 to anti-inflammatory M2, and mitigates sepsis-associated liver inflammatory damage.
Cynaroside reduces binding of PKM2 to hypoxia-inducible factor-1α (HIF-1α) by abolishing translocation of PKM2 to the nucleus and promoting PKM2 tetramer formation, as well as suppressing phosphorylation of PKM2 at Y105 in vivo and in vitro.
Cynaroside restores pyruvate kinase activity, inhibits glycolysis-related proteins including PFKFB3, HK2 and HIF-1α, and inhibits glycolysisrelated hyperacetylation of HMGB1 in septic liver.
Cynaroside protects H9c2 cells against H₂O₂-induced apoptosis by decreasing ROS generation and inhibiting caspase activation in both the mitochondrial and death receptor pathways.
Cynaroside maintains mitochondrial function by regulating Bcl-2 protein expression, as well as JNK and P53 expression^[2]^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	RAW264.7 cell
Concentration:	5µM, 10µM
Incubation Time:	2 h
Result:	Reduced expression levels of IL-1β, IL-6 and TNF-α and HMGB1, suppressed M1 polarized phenotype in RAW264.7 cells.

Immunofluorescence^[2]

Cell Line:	RAW264.7 cell
Concentration:
Incubation Time:	4 h
Result:	Decreased PKM2 nuclear translocation in hepatic macrophages of septic mice.

RT-PCR^[2]

Cell Line:	RAW264.7 cell
Concentration:	2.5µM, 5µM, 10µM
Incubation Time:
Result:	Increased increased expression levels of M2 markers Arg-1, IL-10 andCD206.

Cell Viability Assay^[3]

Cell Line:	H9c2 cells
Concentration:	25, 50, 100 μg/mL
Incubation Time:	4 h
Result:	Protected H9c2 cells from oxidative stress-induced cell injury.

Apoptosis Analysis^[3]

Cell Line:	H9c2 cells
Concentration:	25, 50, 100 μg/mL
Incubation Time:	4 h
Result:	Decreased H₂O₂-induced apoptosis in H9C2 cells.

体内実験

Cynaroside (i.p.; 5 mg/kg) reduces binding of PKM2 to hypoxia-inducible factor-1α (HIF-1α) by abolishing translocation of PKM2 to the nucleus and promoting PKM2 tetramer formation, as well as suppressing phosphorylation of PKM2 at Y105^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice model of sepsis^[2]
Dosage:	5mg/kg
Administration:	Cynaroside (i.p.; 5mg/kg)
Result:	Inhibited PKM2 dimer formation in liver of septic mice.

分子量

448.38

分子式

C₂₁H₂₀O₁₁

CAS 番号

5373-11-5

Appearance

Solid

Color

Light yellow to green yellow

SMILES

O=C(C=C(C1=CC(O)=C(O)C=C1)OC2=CC(O[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO)=C4)C2=C4O

Structure Classification

Initial Source

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 83.33 mg/mL (185.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2303 mL	11.1513 mL	22.3025 mL
5 mM	0.4461 mL	2.2303 mL	4.4605 mL
10 mM	0.2230 mL	1.1151 mL	2.2303 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 16.67 mg/mL (37.18 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.37%

Select Batch:

データシート (281 KB) SDS (394 KB)

COA (250 KB) HNMR (306 KB) LCMS (93 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Václav Zima, et al. Unraveling the Anti-Influenza Effect of Flavonoids: Experimental Validation of Luteolin and its Congeners as Potent Influenza Endonuclease Inhibitors. Eur J Med Chem. 22 August 2020, 112754.

[2]. Liuhua Pei, et al. Cynaroside prevents macrophage polarization into pro-inflammatory phenotype and alleviates cecal ligation and puncture-induced liver injury by targeting PKM2/HIF-1α axis. Fitoterapia. 2021 Jul;152:104922. [Content Brief]

[3]. Xiao Sun, et al. Protective effects of cynaroside against H₂O₂-induced apoptosis in H9c2 cardiomyoblasts. J Cell Biochem. 2011 Aug;112(8):2019-29. [Content Brief]

[4]. Shams Tabrez, et al. Cynaroside inhibits Leishmania donovani UDP-galactopyranose mutase and induces reactive oxygen species to exert antileishmanial response. Biosci Rep. 2021 Jan 29;41(1):BSR20203857. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2303 mL	11.1513 mL	22.3025 mL	55.7563 mL
	5 mM	0.4461 mL	2.2303 mL	4.4605 mL	11.1513 mL
	10 mM	0.2230 mL	1.1151 mL	2.2303 mL	5.5756 mL
	15 mM	0.1487 mL	0.7434 mL	1.4868 mL	3.7171 mL
	20 mM	0.1115 mL	0.5576 mL	1.1151 mL	2.7878 mL
	25 mM	0.0892 mL	0.4461 mL	0.8921 mL	2.2303 mL
	30 mM	0.0743 mL	0.3717 mL	0.7434 mL	1.8585 mL
	40 mM	0.0558 mL	0.2788 mL	0.5576 mL	1.3939 mL
	50 mM	0.0446 mL	0.2230 mL	0.4461 mL	1.1151 mL
	60 mM	0.0372 mL	0.1859 mL	0.3717 mL	0.9293 mL
	80 mM	0.0279 mL	0.1394 mL	0.2788 mL	0.6970 mL
	100 mM	0.0223 mL	0.1115 mL	0.2230 mL	0.5576 mL

Cynaroside Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Cynaroside (Synonyms: Luteolin 7-glucoside; Luteolin 7-O-β-D-glucoside)

カスタマーレビュー

Other Forms of Cynaroside:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示:

Parasite アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Cynaroside Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Cynaroside (Synonyms: Luteolin 7-glucoside; Luteolin 7-O-β-D-glucoside)

カスタマーレビュー

Other Forms of Cynaroside:

Cynaroside 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示:

Parasite アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Cynaroside 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Cynaroside Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report